End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
19.39 CNY | -0.10% | +0.47% | -15.95% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.95% | 4.49B | C+ | ||
+41.06% | 6.26B | B- | ||
+6.36% | 3.29B | C | ||
-11.34% | 3.12B | B- | ||
-3.12% | 2.5B | - | D+ | |
+45.41% | 1.94B | - | ||
-7.74% | 1.68B | - | - | |
-0.67% | 1.63B | - | - | |
-11.32% | 1.56B | C- | ||
+49.16% | 1.52B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 002603 Stock
- Ratings Shijiazhuang Yiling Pharmaceutical Co., Ltd.